Technical Analysis for HCM - Hutchison China MediTech Limited

Grade Last Price % Change Price Change
grade F 22.15 0.82% 0.18
HCM closed up 0.82 percent on Friday, January 18, 2019, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical HCM trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 17 1,2,3 Retracement Bearish Bearish Swing Setup 0.82%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.82%
Jan 17 Narrow Range Bar Range Contraction 0.82%
Jan 17 Inside Day Range Contraction 0.82%
Jan 17 Wide Bands Range Expansion 0.82%
Jan 16 Wide Bands Range Expansion 0.73%
Jan 16 Oversold Stochastic Weakness 0.73%
Jan 15 MACD Bullish Signal Line Cross Bullish 0.68%

Older signals for HCM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People's Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.
Is HCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 39.68
52 Week Low 20.83
Average Volume 589,573
200-Day Moving Average 30.5279
50-Day Moving Average 28.9358
20-Day Moving Average 22.802
10-Day Moving Average 21.899
Average True Range 1.312
ADX 30.94
+DI 15.7687
-DI 30.6467
Chandelier Exit (Long, 3 ATRs ) 28.399
Chandelier Exit (Short, 3 ATRs ) 24.766
Upper Bollinger Band 25.8907
Lower Bollinger Band 19.7133
Percent B (%b) 0.39
BandWidth 27.091483
MACD Line -2.0956
MACD Signal Line -2.3706
MACD Histogram 0.275
Fundamentals Value
Market Cap 2.69 Billion
Num Shares 121 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 201.36
Price-to-Sales 15.61
Price-to-Book 19.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.89
Resistance 3 (R3) 22.82 22.52 22.76
Resistance 2 (R2) 22.52 22.33 22.55 22.72
Resistance 1 (R1) 22.33 22.21 22.43 22.40 22.68
Pivot Point 22.03 22.03 22.07 22.06 22.03
Support 1 (S1) 21.84 21.84 21.94 21.91 21.62
Support 2 (S2) 21.54 21.72 21.57 21.58
Support 3 (S3) 21.35 21.54 21.54
Support 4 (S4) 21.42